FDA Expands Approved Uses for Radiopharmaceutical Therapy Pluvicto

The U.S. Food and Drug Administration (FDA) has granted an expanded indication for Pluvicto (lutetium Lu 177 vipivotide tetraxetan). This radiopharmaceutical therapy, used in oncology, now offers new treatment options for a broader patient population, potentially improving outcomes for individuals with certain cancers.